In vitro investigations on dopamine loaded Solid Lipid Nanoparticles

Area of Science:

• Nanotechnology
• Neuroscience
• Pharmaceutics

Background:

• Parkinson's disease (PD) involves the degeneration of dopamine (DA)-producing neurons.
• The Blood-Brain Barrier (BBB) prevents direct therapeutic administration of DA due to its hydrophilicity.
• Intranasal delivery offers a potential route for bypassing the BBB and delivering therapeutics to the brain.

Purpose of the Study:

• To investigate the physicochemical properties of novel Solid Lipid Nanoparticles (SLN) for enhanced brain delivery of dopamine (DA).
• To assess the potential of Glycol Chitosan (GCS)-containing SLN for intranasal administration in Parkinson's disease (PD) therapy.

Main Methods:

• Formulation of novel SLN incorporating dopamine (DA) and Glycol Chitosan (GCS).
• Characterization of SLN size, zeta potential, and DA incorporation efficiency.
• Physicochemical analysis using Fourier-Transform Infrared Spectroscopy in Attenuated Total Reflectance mode (FT-IR/ATR) and Thermogravimetric Analysis (TGA).

Main Results:

• SLN formulated with GCS and DA exhibited smaller particle sizes compared to DA-loaded SLN without GCS.
• The GCS-containing SLN demonstrated a slightly positive zeta potential.
• Remarkably, SLN incorporated 81% of the initial dopamine (DA) content, indicating high encapsulation efficiency.
• FT-IR/ATR and TGA confirmed the solid-state properties and thermal stability of the formulated SLN.

Conclusions:

• The novel GCS-containing SLN are suitable for dopamine (DA) incorporation and exhibit favorable thermal stability.
• These SLN show significant potential for enhancing DA brain delivery via intranasal administration for Parkinson's disease (PD) treatment.
• Further in vitro and in vivo studies are warranted to evaluate their therapeutic efficacy in PD.